“Bimekizumab 3-year Maintenance of Response in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from Five Phase 3/3b Trials”, J of Skin, vol. 8, no. 1, p. s306, Jan. 2024, doi: 10.25251/skin.8.supp.306.